Table III.
Comparison of side effects.
| XELOX-70 vs. XELOX-130 | XELOX-130 vs. FOLFOX-4 | XELOX-70 vs. FOLFOX-4 | |
|---|---|---|---|
| Fatigue (grade) | |||
| 1/2 | 0.141 | 0.028 | 0.324 |
| 3/4 | 0.656 | 0.553 | 0.553 |
| 1–4 | 0.404 | 0.003 | 0.239 |
| Nausea (grade) | |||
| 1/2 | 0.040 | 0.481 | 0.013 |
| 3/4 | 0.301 | 0.420 | 0.562 |
| 1–4 | 0.420 | 0.306 | 0.022 |
| Emesis (grade) | |||
| 1/2 | 0.232 | 0.474 | 0.357 |
| 3/4 | 0.500 | 0.438 | 0.242 |
| 1–4 | 0.076 | 0.627 | 0.132 |
| Diarrhea (grade) | |||
| 1/2 | 0.151 | 0.603 | 0.121 |
| 3/4 | 0.758 | 0.715 | 0.715 |
| 1–4 | 0.062 | 0.581 | 0.109 |
| Mucositis (grade) | |||
| 1/2 | 0.500 | 0.581 | 0.440 |
| 3/4 | n.e. | n.e. | n.e. |
| 1–4 | 0.324 | 0.560 | 0.560 |
| Exanthema (grade) | |||
| 1/2 | 0.360 | 0.140 | 0.034 |
| 3/4 | n.e. | n.e. | n.e. |
| 1–4 | 0.243 | 0.254 | 0.350 |
| PPE (grade) | |||
| 1/2 | 0.241 | 0.560 | 0.175 |
| 3/4 | 0.500 | 0.715 | 0.438 |
| 1–4 | 0.540 | 0.581 | 0.524 |
| Paresthesia (grade) | |||
| 1/2 | 0.344 | 0.209 | 0.498 |
| 3/4 | 0.699 | 0.633 | 0.633 |
| 1–4 | 0.596 | 0.130 | 0.447 |
| Pain (grade) | |||
| 1/2 | 0.500 | 0.037 | 0.016 |
| 3/4 | 0.758 | 0.562 | 0.562 |
| 1–4 | 0.239 | 0.062 | 0.028 |
| Alopecia (grade) | |||
| 1/2 | 0.360 | 0.526 | 0.243 |
| 3/4 | n.e. | n.e. | n.e. |
| 1–4 | 0.243 | 0.526 | 0.147 |
| Loss of weight (grade) | |||
| 1/2 | 0.500 | 0.254 | 0.147 |
| 3/4 | n.e. | n.e. | n.e. |
| 1–4 | 0.373 | 0.254 | 0.128 |
| Infections (grade) | |||
| 1/2 | 0.699 | 0.174 | 0.174 |
| 3/4 | 0.147 | n.e. | n.e. |
| 1–4 | 0.147 | 0.315 | 0.502 |
Comparison of side effects among the used chemotherapy regimens XELOX-70, XELOX-130 and FOLFOX-4. Differences in the grade of toxicity were considered significant using the Fisher test when reaching a maximum p value of p<0.05. PPE, palmar-plantar erythrodysesthesia; n.e., not evaluable.